此次三款药物纳入医保，不仅降低了以往高昂的治疗成本，更通过医保报销机制切实缓解患者的经济压 力，让这份"生命希望"真正变得触手可及。针对临床未满足的需求和治疗费用的降低，科伦博泰总经理 兼首席执行官葛均友博士表示，"当你知道自己的创新研究成果可能改变一个疾病领域的治疗格局，能 够填补目前治疗不了的领域时，那种使命感超越了任何商业考量。虽然医保目录内已有同类治疗产品， 但我们愿意以更加亲民的价格推进国产替代，防止患者因病致贫、因病返贫。" 智通财经APP了解到，1月1日，《国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创 新药品目录(2025年)》正式落地实施。在这份新目录中，科伦博泰生物-B(06990)自主研发的芦康沙妥珠 单抗(佳泰莱)、西妥昔单抗N01(达泰莱)与塔戈利单抗(科泰莱)三款创新药物成功跻身其中。 据悉，对于晚期三阴性乳腺癌患者及EGFR-TKI治疗失败的非小细胞肺癌患者而言，传统治疗手段往往 收效甚微。而作为科伦博泰自主研发的国内首个获完全批准上市的国产ADC(抗体药物偶联物)，芦康沙 妥珠单抗于2024年11月正式获批，用于治疗既往至少接受过2种系统治疗(其中至少1种针对晚期 ...

Core Insights - The company reported a revenue of RMB 950 million for the six months ending June 30, 2025, representing a year-on-year decrease of 31.3% [1] - Research and development expenses amounted to RMB 612 million, down 6.3% year-on-year [1] - The company incurred a loss attributable to equity shareholders of RMB 145 million, with a loss per share of RMB 0.64 [1] Financial Performance - Total commercial sales for the first half of 2025 reached RMB 309.8 million, with 97.6% of sales coming from the product "佳泰莱" [1] - All accounts receivable from drug sales were collected within the payment period, indicating efficient cash flow management [1] Product Development and Pipeline - The company has received marketing approvals for sac-TMT (佳泰莱), Tagolizumab (科泰莱), and Cetuximab N01 (达泰莱) and has commenced commercialization [1] - The company anticipates launching "博度曲妥珠单抗" (舒泰莱) in the Chinese market in the second half of 2025, pending regulatory communication and approval [1] - The company is a pioneer in developing ADCs and has over ten years of experience in this field, with a proprietary platform for ADC and novel conjugated drugs [2] Manufacturing and Quality Management - The company possesses end-to-end manufacturing capabilities that comply with cGMP standards and a comprehensive quality management system to support drug development [2] - The company benefits from the extensive experience, industry relationships, and network of its controlling shareholder, 科伦药业 (002422), which enhances its commercialization infrastructure and market pipeline [2]